Abstract
The recent Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak poses a serious threat to public health. Here, we summarize recent advances in identifying human neutralizing monoclonal antibodies (mAbs) against MERS-CoV, describe their mechanisms of action, and analyze their potential for treatment of MERS-CoV infections.
Keywords:
Coronavirus; MERS-CoV; Receptor binding domain (RBD); mAbs.
Copyright © 2014 Institut Pasteur. All rights reserved.
Publication types
-
Research Support, N.I.H., Intramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Neutralizing / immunology
-
Antibodies, Neutralizing / therapeutic use*
-
Antibodies, Viral / immunology
-
Antibodies, Viral / therapeutic use
-
Communicable Disease Control
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / prevention & control
-
Coronavirus Infections / virology
-
Humans
-
Middle East
-
Middle East Respiratory Syndrome Coronavirus / immunology*
-
Neutralization Tests
Substances
-
Antibodies, Monoclonal
-
Antibodies, Neutralizing
-
Antibodies, Viral